PCM
BEAT

Piermont Capital Management’s BioTelemetry, Inc. BEAT Stock Holding History

Piermont Capital Management’s Portfolio BEAT Stock Details BEAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-24,260
Closed -$811K – 288
2017
Q2 		$811K Sell
24,260
-4,330
-15% -$129K 0.23% 183
2017
Q1 		$828K Hold
28,590
– – 0.2% 181
2016
Q4 		$639K Buy
+28,590
New +$559K 0.15% 206
2016
Q3 		– Sell
-76,842
Closed -$1.25M – 304
2016
Q2 		$1.25M Buy
76,842
+36,852
+92% +$542K 0.32% 113
2016
Q1 		$467K Buy
+39,990
New +$447K 0.15% 155

Other funds holding BEAT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Piermont Capital Management's BEAT Position: Q3 2017 in Review

Piermont Capital Management sold out of BioTelemetry, Inc. (BEAT) in Q3 2017, closing a stake of 24,260 shares — an estimated $811K sold.

Piermont Capital Management first reported a position in BEAT in Q1 2016 and held it in 5 quarters. The position peaked at $1.25M in Q2 2016. 211 funds tracked by Wall St. Rank hold BEAT as of Q3 2017.

  • Piermont Capital Management reported no remaining BioTelemetry, Inc. position as of Q3 2017 after selling out during the quarter.
  • Piermont Capital Management sold 24,260 BioTelemetry, Inc. shares in Q3 2017, an estimated $811K.
  • Piermont Capital Management first reported a position in BioTelemetry, Inc. in Q1 2016 and held it in 5 quarters.
  • Piermont Capital Management's BioTelemetry, Inc. position peaked at $1.25M in Q2 2016.
  • 211 funds tracked by Wall St. Rank held BioTelemetry, Inc. as of Q3 2017.

Based on Piermont Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.